Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGHT MRL: MR-Linac RT in High-Grade Glioma
NCT07457307Phase 1Not yet recruiting
- Sponsor
- NYU Langone Health
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioma, sponsored by NYU Langone Health. Primary endpoint: Overall Occurrence of Dose-Limiting Toxicities at 14 months. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
glioma
Beyond the preview
Go deeper on NCT07457307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457307.